Kala pharmaceuticals, inc. (KALA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-90,914

-94,347

-97,608

-90,035

-80,829

-66,738

-52,809

-47,382

-43,749

-42,211

0

0

0

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

903

843

723

567

441

352

317

320

299

287

0

0

0

Non-cash operating lease cost

1,809

1,773

0

0

0

-

-

-

-

-

-

-

-

Amortization of right-of-use assets

-

-

-

-

-

-

-

-

362

356

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

1,844

0

0

0

Amortization of debt discount and other non-cash interest

980

958

0

0

0

-

-

-

-

-

-

-

-

Amortization of debt discount and other non-cash interest

-

-

-

-

-

-

-

-

0

-

0

0

0

Stock-based compensation

10,015

9,991

9,864

9,557

9,227

8,615

7,918

6,634

4,910

3,571

0

0

0

Change in operating assets and liabilities:
Accounts receivable

120

11,563

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,309

1,789

-1,796

293

527

1,387

3,112

334

643

494

0

0

0

Inventory

3,794

4,271

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

-896

-2,770

1,024

754

1,111

4,088

-89

1,098

-1,215

205

0

0

0

Accrued expenses and other current liabilities

4,373

9,630

6,279

7,204

6,118

3,968

3,907

1,154

1,055

2,601

0

0

0

Lease liabilities and other long-term liabilities

-1,477

-1,175

0

0

0

-

-

-

-

-

-

-

-

Lease liabilities and other long-term liabilities

-

-

-

-

-

-

-

-

-371

-361

0

0

0

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in operating activities

-81,430

-92,720

-90,497

-83,798

-72,577

-54,121

-44,696

-37,813

-37,455

-34,098

0

0

0

Cash flows from investing activities:
Purchases of property and equipment

1,183

1,335

2,057

1,980

1,649

1,578

950

912

781

480

0

0

0

Net cash used in investing activities

-1,183

-1,335

-2,057

-1,980

-1,649

-1,578

-950

-912

-781

-480

0

0

0

Cash flows from financing activities:
Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from common stock offerings, net of underwriters' discounts and offering cost

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from venture debt, net of debt issuance costs of $50

-

-

-

-

-

-

0

0

0

-

-

-

-

Payment of principal and prepayment penalty on venture debt

-

-

-

-

-

21,847

0

0

0

-

-

-

-

Payment of principal on finance lease

28

30

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan

0

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan

-

-

-

-

-

-

-

0

0

-

-

-

-

Net cash provided by financing activities

140,134

8,982

125,602

122,979

123,044

124,104

552

105,624

104,804

103,696

0

0

0

Net increase/(decrease) in cash and restricted cash:

57,521

-85,073

33,048

37,201

48,818

68,405

-45,094

66,899

66,568

69,118

0

0

0

Reconciliation of cash and restricted cash:
Less restricted cash

-

-

-

-

-

-

-

-

-

134

0

0

0

Non-cash investing and financing activities:
Right-of-use asset obtained in exchange for finance lease obligation

-

136

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment in accounts payable

-

-

-

-

0

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accruals

-

-

-

-

-

-

-

-

-

-

-

0

0

Supplemental disclosure:
Cash paid for interest

7,535

7,522

7,529

5,924

4,497

3,041

1,469

1,315

1,099

863

0

0

0

Right-of-use assets obtained in exchange of operating lease obligations

-

1,852

0

0

0

-

-

-

-

-

-

-

-